Scilex Holding Company (SCLX)
SCLX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1820190/000119312526151455/0001193125-26-151455-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | SCLX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001820190 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $30.3M |
| Net income | -$374.1M |
| Operating income | -$346.0M |
| Net margin | -1236.4% |
| Operating margin | -1143.7% |
| Revenue growth | -46.5% |
| Cash | $5.0M |
| Total assets | $365.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company's ability to continue as a going concern for one year after the date the unaudited condensed consolidated financial statements are issued. 3." | 10-Q 2026-08-14 |
| Cash and burn | $566K cash; operating cash flow -$4.3M a quarter. | Report 2026-06-30 |
| Shares outstanding | 8,493,000 (2026-08-10); 6,955,697 a year earlier; 149,055,371 three years earlier. 1y figure adjusted for splits (1.606-for-1 overall); 3y figure adjusted for splits (1-for-21.793 overall). | Cover page 2026-08-10 |
| Reverse splits, 3 years | 1; latest 1-for-35 on 2025-04-15 | Source 2025-04-15 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-06-02 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BPM LLP, Walnut Creek, California, United States; changed auditors 3 times in 24 months | 8-K 4.01 2024-12-06 |
| Late filings, 12 months | 2 NT notices | NT 10-Q 2026-05-15 |
| Insider trades, 12 months | Bought $0, sold $2.8M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $7.6M | -$115.0M | -$6.7M | $566K | $80.8M | $31.6M | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $8.6M | -$45.6M | -$1.1M | $3.4M | $80.8M | $33.9M | 10-Q 2026-05-20 |
| Q4 2025 2025-12-31 | $4.8M | -$46.1M | -$17.5M | $5.0M | $105.7M | $30.3M | 10-K 2026-04-10 |
| Q3 2025 2025-09-30 | $10.6M | -$257.8M | $8.2M | $878K | $45.7M | $40.4M | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | $9.9M | -$44.0M | $7.0M | $4.1M | $39.9M | $44.2M | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $5.0M | -$26.1M | $6.0M | $5.8M | $39.4M | $50.7M | 10-Q 2026-05-20 |
| Q4 2024 2024-12-31 | $14.9M | -$6.5M | $2.5M | $3.3M | $35.7M | $56.6M | 10-K 2026-04-10 |
| Q3 2024 2024-09-30 | $14.4M | -$4.4M | $5.1M | $77K | $99.0M | $55.2M | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-06-02 |
| Latest annual report | 10-K | 2026-04-10 |
| Latest quarterly / interim | 10-Q | 2026-08-14 |
| Latest current report | 8-K | 2026-09-29 |
| Latest proxy | DEFA14A | 2026-05-05 |
Source: SEC EDGAR submissions feed, 742 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -15.9% |
| 1 month | -50.3% |
| 3 months | -78.8% |
| Year to date | -81.2% |
| 1 year | -87.1% |
| From 52-week high | -89.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| SCLXW | Scilex Holding Company Warrant | $0.0263 |
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ALGS | Aligos Therapeutics Inc. | $1.66 | -20.95% | $10.4M |
| INTS | Intensity Therapeutics Inc. | $3.07 | -0.32% | $10.1M |
| BCDA | BioCardia Inc. | $0.7901 | -4.92% | $12.0M |
| TCRX | TScan Therapeutics Inc. | $0.1451 | -9.65% | $9.2M |
| INAB | IN8bio Inc. | $0.8160 | -0.49% | $8.8M |
| DYAI | Dyadic International Inc. | $0.3200 | -2.14% | $12.8M |
| JSPR | Jasper Therapeutics Inc. | $11.77 | -13.96% | $13.1M |
| PASG | Passage Bio Inc. | $4.13 | -2.82% | $13.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier